Our technology: unique, potent stem cell therapeutics from an expert, pioneering manufacturer.
We use cutting-edge, in-house process technology and quality control systems to generate state-of-the-art stem cells and ATMPs (Advanced Therapy Medicinal Products) in line with AMG (German Medicinal Products Act) requirements.
TICEBA holds an exclusive license to the full ABCB5 gene and protein patent portfolio from Boston Children's Hospital, a teaching affiliate of Harvard Medical School, Boston, Massachusetts (37+ exclusive patents).
Our ground-breaking ABCB5 research has received widespread coverage in peer-reviewed academic journals, leading to high-end potency assays, translating research into clinical efficacy.
Off-the-shelf & ready to use: covering the full clinical development spectrum from CMC through to market launch
High through-put stem cell production based on globally patented technology and expertise - catering for world-wide market needs - anytime, anyplace, anywhere.
Tried and tested, high-potential technology – heralding the arrival of next-generation cell therapies
Our tried and tested, patented technology platform nurturing next-generation technologies (CRISPR/Cas, iPS Technology and 3D Bioprinting) heralds the arrival of next-generation cell therapies.
a Agency-regulated tissue removal centers
b Patented technology: 37 exclusive patents with Harvard University
c Ballikaya et al., Stem Cell Res Ther. 2020/Kerstan et al., Cytotherapy. 2021
d Isolation of ABCB5-positive mesenchymal stem cells